Related Experiment Video

Updated: May 5, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

29.4K

Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary

S M Clee1, A H Zwinderman, J C Engert

  • 1Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.

Circulation
|March 10, 2001
PubMed

Insights

Common variations in the ATP-binding cassette transporter 1 (ABCA1) gene impact high-density lipoprotein cholesterol (HDL-C) levels and coronary artery disease (CAD) risk. The R219K variant is linked to slower atherosclerosis progression and reduced CAD severity.

Area of Science:

  • Genetics and Cardiovascular Disease
  • Molecular Biology and Lipid Metabolism

Background:

  • Low high-density lipoprotein cholesterol (HDL-C) is a known risk factor for coronary artery disease (CAD).
  • The ATP-binding cassette transporter 1 (ABCA1) gene is crucial for cholesterol efflux and HDL production.
  • Genetic variations in ABCA1 are linked to HDL deficiency, dyslipidemia, and increased CAD risk.

Purpose of the Study:

  • To investigate the influence of common genetic variations within the ABCA1 gene on plasma lipid levels.
  • To determine the association between ABCA1 gene polymorphisms and the severity of coronary artery disease (CAD) in the general population.

Main Methods:

  • Analysis of phenotypic effects of single nucleotide polymorphisms (SNPs) in the coding region of the ABCA1 gene.
  • Examining the carrier frequency of the R219K variant in European populations.
  • Assessing the impact of the R219K variant on CAD severity, atherosclerosis progression, plasma lipid levels, and coronary events.

Main Results:

  • The R219K variant, with a 46% carrier frequency in Europeans, was associated with reduced CAD severity and slower atherosclerosis progression.
  • Carriers of R219K showed decreased focal and diffuse atherosclerosis and fewer coronary events compared to non-carriers.
  • R219K carriers exhibited decreased triglyceride levels and a trend towards increased HDL-C levels.

Conclusions:

  • Common variations in the ABCA1 gene significantly influence plasma lipid profiles.
  • Genetic variation in ABCA1 plays a substantial role in determining the severity of coronary artery disease (CAD).
Abstract

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

8.4K
High-Density Lipoprotein-Specific Phospholipid Efflux Assay07:08

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

564

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741